Noopur Raje, MD, on Current CAR T Options in Multiple Myeloma

Video

The director of the Center for Multiple Myeloma at Mass Gen discussed current CAR T-cell therapies in multiple myeloma.

This content originally appeared on our sister site, OncLive.

Chimeric antigen receptor (CAR) T-cell therapies are a growing option for the treatment of multiple myeloma. Idecabtagene vicleucel (ide-cel; Abecma) was approeved in March 2021 for the treatment of patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy. Ciltacabtagene autoleucel (cilta-cel; Carvykti) was apprpved in February 2022 for the treatment of adult patients with relapsed/refractory multiple myeloma following 4 or more prior lines of therapy.

Patients eligible for CAR T-cell therapy treatment have highly refractory disease and have been exposed to a majority of treatment options, including lenalidomide (Revlimid), pomalidomide (Pomalyst), bortezomib (Velcade), carfilzomib (Kyprolis), and an anti-CD38 monoclonal antibody.

OncLive spoke with Noopur Raje, MD, to learn more about the current CAR T-cell therapy options available for patients with relapsed/refractory multiple myeloma.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.